Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

A recent study found that following a plant-based diet could significantly reduce the risk of VTE, or venous thromboembolism ...

Purpose Published evidence on the incidence and predictors of venous thromboembolism (VTE) in patients with cirrhosis of the liver is reviewed. Summary The frequently observed phenomenon of ...

Elevated fibrinogen levels can contribute to a hypercoagulable state by increasing blood viscosity, red blood cell red blood cell and platelet aggregation, and platelet activity, reducing blood flow ...

Objective: Assess the extent to which rebound hypercoagulability-related VTE recurrences occur in the 2 months following discontinuation of OACs. Data sources: Published, randomized controlled ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban (Eliquis) was just as effective as a higher dose -- and safer ...

Extended treatment with low-dose apixaban was noninferior to a full dose for preventing cancer-related VTE. Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring ...

The long-term incidence of MACE, VTE, and malignancies is low among patients with RA or UC receiving filgotinib, though a slight increase was observed among older patients.